A5019749214- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Manufacturing Process and Optimization
- Chronic Myeloid Leukemia Treatments
- Additive Manufacturing and 3D Printing Technologies
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- Cancer-related Molecular Pathways
- Advanced machining processes and optimization
- Advanced Measurement and Metrology Techniques
- Additive Manufacturing Materials and Processes
- Multiple Myeloma Research and Treatments
- Design Education and Practice
- Acute Myeloid Leukemia Research
- Gastrointestinal Tumor Research and Treatment
- Galectins and Cancer Biology
- Childhood Cancer Survivors' Quality of Life
- Calcium signaling and nucleotide metabolism
- Glycosylation and Glycoproteins Research
- SARS-CoV-2 detection and testing
- Multiple and Secondary Primary Cancers
- CAR-T cell therapy research
University of Bath
2015-2023
Norton Healthcare
2016-2021
The Ohio State University
2008-2017
Sylvester Comprehensive Cancer Center
2015
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2011-2014
Columbus Oncology and Hematology Associates
2013-2014
The Ohio State University Wexner Medical Center
2008-2014
Palmetto Hematology Oncology
2009
Sarah Cannon
2009
University of Alabama at Birmingham
2009
<h3>Importance</h3> The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy this drug and outcomes following discontinuation have not been evaluated outside of clinical trials relatively short follow-up. <h3>Objective</h3> To determine features associated outcomes. <h3>Design, Setting, Participants</h3> A total 308 participating 4 sequential at Ohio State University Comprehensive Cancer Center...
Purpose Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift therapy, and relapse been uncommon current follow-up. Acquired mutations BTK PLCG2 can cause relapse, but data regarding the prevalence natural history these are limited. Patients Methods accrued four sequential studies were included analyses. Deep sequencing for was performed retrospectively on patients who experienced prospectively screening population....
BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2–inducible T cell (ITK). The relative importance of these 2 kinases not examined despite its relevance immune-based therapies.
Patients with chronic lymphocytic leukemia (CLL) high-risk genomic features achieve poor outcomes traditional therapies. A phase I study of a pharmacokinetically derived schedule flavopiridol suggested promising activity in CLL, irrespective features. Given the relevance these findings to treating genetically prospective confirmatory was initiated.
Cancer is the leading cause of death among adolescent and young adult (AYA) population, excluding homicide, suicide, or unintentional injury. AYA patients should be managed by a multidisciplinary team health care professionals who are well-versed in specific developmental issues relevant to this patient population. The recommendations for age-appropriate outlined these NCCN Guidelines include psychosocial assessment, discussion infertility risks associated with treatment options fertility...
Tetraspanins are commonly believed to act only as "molecular facilitators," with no direct role in signal transduction. We herein demonstrate that upon ligation, CD37, a tetraspanin molecule expressed on mature normal and transformed B cells, becomes tyrosine phosphorylated, associates proximal signaling molecules, initiates cascade of events leading apoptosis. Moreover, we have identified two residues opposing regulatory functions: one lies the N-terminal domain CD37 predicted "ITIM-like"...
The NCCN Guidelines Insights on Adolescent and Young Adult (AYA) Oncology discuss the fertility endocrine issues that are relevant to management of AYA patients with cancer. Fertility preservation should be an essential part in treatment recommend discussion contraception before start treatment. Oophoropexy embryo cryopreservation 2 established options for women. Semen is most reliable well-established method preserving men. women cancer also have unique needs, depending type cancer, its...
Abstract CD19 is a B cell–specific antigen expressed on chronic lymphocytic leukemia (CLL) cells but to date has not been effectively targeted with therapeutic monoclonal antibodies. XmAb5574 novel engineered anti-CD19 antibody modified constant fragment (Fc)–domain designed enhance binding of FcγRIIIa. Herein, we demonstrate that mediates potent antibody-dependent cellular cytotoxicity (ADCC), modest direct cytotoxicity, and phagocytosis complement-mediated against CLL cells. Interestingly,...
Summary Richter Syndrome, an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia ( CLL ), has a generally poor prognosis and anthracycline‐based chemoimmunotherapy regimens designed to treat de novo diffuse large B‐cell achieve modest clinical benefit. R‐ EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) demonstrated greater activity against histologies but not been studied Syndrome. We conducted retrospective cohort study of 46...